Bioenergetics and synaptic plasticity as potential targets for individualizing treatment for depression
•Synaptic plasticity modulation is central to antidepressant relief strategies.•Disruptions of bioenergetic signaling directly impact synaptic plasticity.•Cellular stress, inflammation, and metabolism extensively influence bioenergetics.•Bioenergetic biomarkers must be identified for improved treatm...
Saved in:
Published in | Neuroscience and biobehavioral reviews Vol. 90; pp. 212 - 220 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Elsevier Ltd
01.07.2018
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | •Synaptic plasticity modulation is central to antidepressant relief strategies.•Disruptions of bioenergetic signaling directly impact synaptic plasticity.•Cellular stress, inflammation, and metabolism extensively influence bioenergetics.•Bioenergetic biomarkers must be identified for improved treatment design.•Biology-based individualized medicine will improve antidepressant treatment outcome.
Disruptions of bioenergetic signaling and neurogenesis are hallmarks of depression physiology and are often the product of dysregulation of the inflammatory, stress-response, and metabolic systems. These systems are extensively interrelated at the physiological level, yet the bulk of the literature to date addresses pathophysiological mechanisms in isolation. A more integrated understanding of the etiology, progression, and treatment response profiles of depression is possible through wider consideration of relevant preclinical and clinical studies that examine the result of disruptions in these systems. Here, we review recent data demonstrating the critical effects of bioenergetic disruption on neuroplasticity and the development and progression of depressive illness. We further highlight the interactive and dynamic nature of the inflammatory and stress response systems and how disruption of these systems influences bioenergetic signaling pathways critical to treatment outcomes. In so doing, we underscore the pressing need to reconsider the implications of treatment resistance and present a framework for developing novel, personalized treatment approaches for depression. |
---|---|
Bibliography: | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 |
ISSN: | 0149-7634 1873-7528 1873-7528 |
DOI: | 10.1016/j.neubiorev.2018.04.002 |